Literature DB >> 25977090

Pharmacological disruption of maladaptive memory.

Jane R Taylor1, Mary M Torregrossa.   

Abstract

Many psychiatric disorders are characterized by intrusive, distracting, and disturbing memories that either perpetuate the illness or hinder successful treatment. For example, posttraumatic stress disorder (PTSD) involves such strong reemergence of memories associated with a traumatic event that the individual feels like the event is happening again. Furthermore, drug addiction is characterized by compulsive use and repeated relapse that is often driven by internal memories of drug use and/or by exposure to external stimuli that were associated with drug use. Therefore, identifying pharmacological methods to weaken the strength of maladaptive memories is a major goal of research efforts aimed at finding new treatments for these disorders. The primary mechanism by which memories could be pharmacologically disrupted or altered is through manipulation of memory reconsolidation. Reconsolidation occurs when an established memory is remembered or reactivated, reentering a labile state before again being consolidated into long-term memory storage. Memories are subject to disruption during this labile state. In this chapter we will discuss the preclinical and clinical studies identifying potential pharmacological methods for disrupting the integrity of maladaptive memory to treat mental illness.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25977090     DOI: 10.1007/978-3-319-16522-6_13

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  10 in total

Review 1.  Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Authors:  Liana Fattore; Alessandro Piva; Mary Tresa Zanda; Guido Fumagalli; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

Review 2.  Reconsolidation and psychopathology: Moving towards reconsolidation-based treatments.

Authors:  Amber B Dunbar; Jane R Taylor
Journal:  Neurobiol Learn Mem       Date:  2016-11-09       Impact factor: 2.877

Review 3.  New Learning and Unlearning: Strangers or Accomplices in Threat Memory Attenuation?

Authors:  Roger L Clem; Daniela Schiller
Journal:  Trends Neurosci       Date:  2016-04-12       Impact factor: 13.837

4.  The Naturally Occurring Compound Garcinia Indica Selectively Impairs the Reconsolidation of a Cocaine-Associated Memory.

Authors:  Melissa S Monsey; Hayde Sanchez; Jane R Taylor
Journal:  Neuropsychopharmacology       Date:  2016-07-06       Impact factor: 7.853

5.  A high working memory load prior to memory retrieval reduces craving in non-treatment seeking problem drinkers.

Authors:  Anne Marije Kaag; Anna E Goudriaan; Taco J De Vries; Tommy Pattij; Reinout W Wiers
Journal:  Psychopharmacology (Berl)       Date:  2017-11-27       Impact factor: 4.530

6.  Inhibition of Pyramidal Neurons in the Basal Amygdala Promotes Fear Learning.

Authors:  Megan Tipps; Ezequiel Marron Fernandez de Velasco; Allee Schaeffer; Kevin Wickman
Journal:  eNeuro       Date:  2018-10-31

7.  Regulation of Garcinol on Histone Acetylation in the Amygdala and on the Reconsolidation of a Cocaine-Associated Memory.

Authors:  Melissa S Monsey; Sonia G Ruiz; Jane R Taylor
Journal:  Front Behav Neurosci       Date:  2020-01-08       Impact factor: 3.558

8.  Berberine Facilitates Extinction and Prevents the Return of Fear.

Authors:  Shihao Huang; Yu Zhou; Feilong Wu; Cuijie Shi; He Yan; Liangpei Chen; Chang Yang; Yixiao Luo
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810

9.  Inhibition of protein synthesis but not β-adrenergic receptors blocks reconsolidation of a cocaine-associated cue memory.

Authors:  Amber B Dunbar; Jane R Taylor
Journal:  Learn Mem       Date:  2016-07-15       Impact factor: 2.460

10.  Effects of Trace Amine-associated Receptor 1 Agonists on the Expression, Reconsolidation, and Extinction of Cocaine Reward Memory.

Authors:  Jian-Feng Liu; David A Thorn; Yanan Zhang; Jun-Xu Li
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.